Vittia (VITT3) Q2 2024 earnings summary

Executive summary

• Net revenue in Q2 2024 rose 37.3% year-over-year to R$99.9 million, with all segments showing growth; H1 2024 net revenue was R$221.5 million, nearly flat year-over-year.

• Adjusted gross revenue from the biological segment surged 76.2% in Q2 2024 and 8% in H1 2024 year-over-year.

• Net income was negative R$17.7 million in Q2 2024, a 21.6% improvement year-over-year; H1 2024 net income was negative R$16.9 million, a 740.8% increase in losses versus H1 2023.

• Adjusted EBITDA was negative R$18.1 million in Q2 2024 and negative R$11.3 million in H1 2024.

• The company is transitioning to a more favorable outlook for the 2024/2025 grain harvest after a challenging prior year.

Financial highlights

• Capex in Q2 2024 was R$10.4 million, down 34.8% year-over-year; H1 2024 capex was R$17.4 million, down 37.3%.

• SG&A expenses increased 13.8% in H1 2024, driven by higher commercial investments and provisions.

• Net debt reduced by 10.5% year-over-year, despite over R$70 million in provision and repurchase expenses.

• Gross margin for H1 2024 was 27.7%, down from 31.3% in H1 2023.

• Cash and equivalents decreased to R$38.8 million from R$82.8 million at year-end 2023.

Outlook and guidance

• Constructive outlook for the 2024/2025 grain harvest, with positive exchange rates, expected La Niña, reduced stocks, and lower input costs.

• Price stabilization anticipated in the second semester, with some product lines possibly recovering modestly.

• Margin stabilization expected, with a target to zero the drop in soil conditioners and organominerals.

• EBITDA expected to improve as SG&A remains under control and margins recover.

• Continued investment in R&D for biologicals and strengthening of commercial relationships.